Barclays PLC Has $376,000 Holdings in Omeros Co. (NASDAQ:OMER)

Barclays PLC grew its stake in shares of Omeros Co. (NASDAQ:OMER) by 121.3% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 94,640 shares of the biopharmaceutical company’s stock after purchasing an additional 51,873 shares during the period. Barclays PLC owned about 0.16% of Omeros worth $376,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of OMER. Geode Capital Management LLC raised its position in Omeros by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock valued at $5,318,000 after buying an additional 6,839 shares during the last quarter. State Street Corp grew its position in Omeros by 0.3% in the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after purchasing an additional 3,839 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Omeros by 4.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock valued at $1,926,000 after buying an additional 18,454 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Omeros by 16.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after buying an additional 31,081 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Omeros by 6.1% in the second quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock valued at $454,000 after acquiring an additional 6,435 shares in the last quarter. Institutional investors own 48.79% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on OMER shares. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 price target on shares of Omeros in a report on Thursday. Rodman & Renshaw initiated coverage on Omeros in a research note on Thursday, November 14th. They set a “buy” rating and a $9.00 price target for the company. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Finally, StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Omeros currently has an average rating of “Moderate Buy” and an average price target of $22.50.

Omeros Stock Up 1.6 %

Shares of NASDAQ OMER opened at $9.33 on Friday. The company has a market cap of $540.67 million, a P/E ratio of -4.04 and a beta of 2.01. Omeros Co. has a 52 week low of $2.61 and a 52 week high of $13.60. The business has a 50-day simple moving average of $9.35 and a two-hundred day simple moving average of $6.01.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.